Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts

Journal of Cardiothoracic Surgery

Volumn 6, Issue 1, 2011, Pages

  Zou, Junjie ^a   Zhang, Xiwei ^a   Yang, Hongyu ^a   Zhu, Yi ^a   Ma, Hao ^a   Wang, Shui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; NANOPARTICLE; RAPAMYCIN;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GRAFT SURVIVAL; HYPERPLASIA; JUGULAR VEIN; MALE; NEOINTIMA; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY; TRANSPLANTATION; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GRAFT SURVIVAL; HYPERPLASIA; JUGULAR VEINS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MUSCLE, SMOOTH, VASCULAR; NANOPARTICLES; NEOINTIMA; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 79955820421     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-6-69     Document Type: Article

References (25)

1. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS, . PREVENT III Investigators Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006, 43:742-751. 10.1016/j.jvs.2005.12.058, 16616230, PREVENT III Investigators.
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT, . PREVENT IV Investigators Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005, 294:2446-2454. PREVENT IV Investigators.
3. Schwartz SM, deBlois D, O'Brien ER. The intima soil for atherosclerosis and restenosis. Circ Res 1995, 77:445-465.
4. Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial Post CABG Trial Investigators. Circulation 1999, 99:3241-3247.
5. Murphy GJ, Newby AC, Jeremy JY, Baumbach A, Angelini GD. A randomized trial of an external Dacron sheath for the prevention of vein graft disease: the Extent Study. J Thorac Cardiovasc Surg 2007, 134:504-505. 10.1016/j.jtcvs.2007.01.092, 17662798.
6. Murphy GJ, Johnson TW, Chamberlain MH, Rizvi SI, Wyatt M, George SJ, Angelini GD, Karsch KR, Oberhoff M, Newby AC. Short-and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts. Cardiovas Res 2007, 73:607-617.
7. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169. 10.1042/BJ20031253, 1223843, 14505488.
8. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 2002, 16:1217-1226. 10.1096/fj.02-0088com, 12153989.
9. Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J, Samuel J. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A 2008, 84:885-898.
10. Leroueil-Le Verger M, Fluckiger L, Kim YI, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998, 46:137-143. 10.1016/S0939-6411(98)00015-0, 9795032.
11. Schachner T, Zou Y, Oberhuber A, Mairinger T, Tzankov A, Laufer G, Ott H, Bonatti J. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 2004, 25:585-590. 10.1016/j.ejcts.2003.07.013, 15037276.
12. Zou Y, Dietrich H, Hu Y, Metzler B, Wick G, Xu Q. Mouse model of venous bypass graft disease. Am J Pathol 1998, 153:1301-1310. 10.1016/S0002-9440(10)65675-1, 1853044, 9777962.
13. Holt DW, Lee T, Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin Therap 2000, 22:B38-B48.
14. Moon JI, Kim YS, Kim MS, Kim EH, Kim HJ, Kim SI, Park K. Effect of cyclosporine, mycophenolic acid and rapamycin on the proliferation of rat aortic vascular smooth muscle cells. Transplant Proc 2000, 32:2026-2027. 10.1016/S0041-1345(00)01542-6, 11120050.
15. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits smooth muscle cell migration. J Clin Invest 1996, 98:2277-2283. 10.1172/JCI119038, 507677, 8941644.
16. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27kip1 in vascular smooth muscle cell migration. Circulation 2001, 103:2967-2972.
17. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004, 25:902-919. 10.1016/j.ehj.2004.03.023, 15172462.
18. Schachner T, Zou Y, Oberhuber A, Tzankov A, Mairinger T, Laufer G, Bonatti JO. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 2004, 77:1580-1585. 10.1016/j.athoracsur.2003.10.008, 15111146.
19. Fulton GJ, Davies MG, Barber L, Svendsen E, Hagen PO. Locally applied antisense oligonucleotide to proliferating cell nuclear antigen inhibits intimal thickening in experimental vein grafts. Ann Vasc Surg 1998, 12:412-417. 10.1007/s100169900177, 9732417.
20. Walpotha BH, Pavliceka M, Celika B, Nicolaus B, Schaffner T, Althaus U, Hess OM, Carrel T, Morris RE. Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001, 19:487-492. 10.1016/S1010-7940(01)00582-6, 11306318.
21. Rajathurai T, Rizvi SI, Lin H, Angelini GD, Newby AC, Murphy GJ. Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts. Circ Cardiovasc Interv 2010, 3:157-165. 10.1161/CIRCINTERVENTIONS.109.864660, 20332383.
22. Kawatsu S, Katsuhiko O, Saiki Y, Tabata Y, Tabayashi K. External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg 2007, 84:560-567. 10.1016/j.athoracsur.2007.02.034, 17643635.
23. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv 2008, 1:209-216. 10.1161/CIRCINTERVENTIONS.108.830018, 20031680.
24. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK, Fiedler W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004, 300:65-71. 10.1016/j.yexcr.2004.07.002, 15383315.
25. Cejna M, Virmani R, Jones R, Bergmeister H, Losert U, Xu Z, Yang P, Schoder M, Lammer J. Biocompatibility and performance of the Wallstent and several covered stents in a sheep iliac artery model. J Vasc Interv Radiol 2001, 12:351-358. 10.1016/S1051-0443(07)61916-2, 11287514.